메뉴 건너뛰기




Volumn 6, Issue , 2007, Pages

Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B100; ATORVASTATIN; CHOLESTEROL; ENFUVIRTIDE; EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; TRIACYLGLYCEROL; ANTIRETROVIRUS AGENT; AZETIDINE DERIVATIVE; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

EID: 34447626869     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-6-15     Document Type: Article
Times cited : (47)

References (9)
  • 1
    • 0037103407 scopus 로고    scopus 로고
    • Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?
    • 12154337
    • Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? D Klein LB Hurley CP Quesenberry Jr. S Sidney, J Acquir Immune Defic Syndr 2002 30 471 477 12154337
    • (2002) J Acquir Immune Defic Syndr , vol.30 , pp. 471-477
    • Klein, D.1    Hurley, L.B.2    Quesenberry Jr., C.P.3    Sidney, S.4
  • 2
    • 1642403331 scopus 로고    scopus 로고
    • Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men
    • 10.1097/00002030-200311210-00010. 14600519
    • Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. M Mary-Krause L Cotte A Simon M Partisani D Costagliola, Aids 2003 17 2479 2486 10.1097/00002030-200311210-00010 14600519
    • (2003) Aids , vol.17 , pp. 2479-2486
    • Mary-Krause, M.1    Cotte, L.2    Simon, A.3    Partisani, M.4    Costagliola, D.5
  • 3
    • 0042832397 scopus 로고    scopus 로고
    • Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group
    • 10.1086/378131. 12942391
    • Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. MP Dube JH Stein JA Aberg CJ Fichtenbaum JG Gerber KT Tashima WK Henry JS Currier D Sprecher MJ Glesby, Clin Infect Dis 2003 37 613 627 10.1086/378131 12942391
    • (2003) Clin Infect Dis , vol.37 , pp. 613-627
    • Dube, M.P.1    Stein, J.H.2    Aberg, J.A.3    Fichtenbaum, C.J.4    Gerber, J.G.5    Tashima, K.T.6    Henry, W.K.7    Currier, J.S.8    Sprecher, D.9    Glesby, M.J.10
  • 5
    • 4644256971 scopus 로고    scopus 로고
    • Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin
    • 10.1016/j.ahj.2004.03.052. 15389231
    • Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. E Stein S Stender P Mata P Sager D Ponsonnet L Melani L Lipka R Suresh D Maccubbin E Veltri, Am Heart J 2004 148 447 455 10.1016/j.ahj.2004.03. 052 15389231
    • (2004) Am Heart J , vol.148 , pp. 447-455
    • Stein, E.1    Stender, S.2    Mata, P.3    Sager, P.4    Ponsonnet, D.5    Melani, L.6    Lipka, L.7    Suresh, R.8    MacCubbin, D.9    Veltri, E.10
  • 6
    • 18744365508 scopus 로고    scopus 로고
    • Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia
    • 10.1093/eurheartj/ehi231. 15781429
    • Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. M Farnier MW Freeman G Macdonell I Perevozskaya MJ Davies YB Mitchel B Gumbiner, Eur Heart J 2005 26 897 905 10.1093/eurheartj/ehi231 15781429
    • (2005) Eur Heart J , vol.26 , pp. 897-905
    • Farnier, M.1    Freeman, M.W.2    MacDonell, G.3    Perevozskaya, I.4    Davies, M.J.5    Mitchel, Y.B.6    Gumbiner, B.7
  • 7
    • 33746710000 scopus 로고    scopus 로고
    • Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients
    • 16868453
    • Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. B Coll G Aragones S Parra C Alonso-Villaverde L Masana, AIDS 2006 20 1675 1677 16868453
    • (2006) AIDS , vol.20 , pp. 1675-1677
    • Coll, B.1    Aragones, G.2    Parra, S.3    Alonso-Villaverde, C.4    Masana, L.5
  • 9
    • 11344293751 scopus 로고    scopus 로고
    • Cardiovascular risk and body-fat abnormalities in HIV-infected adults
    • 10.1056/NEJMra041811. 15635112
    • Cardiovascular risk and body-fat abnormalities in HIV-infected adults. S Grinspoon A Carr, N Engl J Med 2005 352 48 62 10.1056/NEJMra041811 15635112
    • (2005) N Engl J Med , vol.352 , pp. 48-62
    • Grinspoon, S.1    Carr, A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.